Galapagos NV

Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis

10 يوليو 2021 05:10:00 بحسب Nasdaq GlobeNewswire

Galapagos announces departure of CSO Piet Wigerinck later this year

22 يونيو 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

07 يونيو 2021 16:01:00 بحسب Nasdaq GlobeNewswire

SELECTION study on filgotinib in ulcerative colitis published in The Lancet

04 يونيو 2021 01:01:00 بحسب Nasdaq GlobeNewswire

Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress

27 مايو 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting

18 مايو 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Galapagos refocuses pipeline and rightsizes operations  

06 مايو 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Transparency notification received from The Capital Group

04 مايو 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Galapagos creates new subscription right plans

30 أبريل 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies

23 أبريل 2021 00:01:00 بحسب Nasdaq GlobeNewswire

Extension of lock-up period in Gilead-Galapagos collaboration agreement

08 أبريل 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Publication of the annual report and invitation to the ordinary shareholders’ meeting

25 مارس 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Galapagos appoints Bart Filius as President and Chief Operating Officer

24 مارس 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

19 مارس 2021 17:01:00 بحسب Nasdaq GlobeNewswire

GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES

04 مارس 2021 01:49:18 بحسب Nasdaq GlobeNewswire

Transparency notification received from The Capital Group

03 مارس 2021 16:15:00 بحسب Nasdaq GlobeNewswire

Pipeline and capital for growth

18 فبراير 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

10 فبراير 2021 09:00:00 بحسب Nasdaq GlobeNewswire

The Capital Group holds 10.03% of Galapagos shares

09 فبراير 2021 16:01:01 بحسب Nasdaq GlobeNewswire

NICE recommends Jyseleca® ▼(filgotinib) on NHS in landmark decision for rheumatoid arthritis

21 يناير 2021 02:08:24 بحسب Nasdaq GlobeNewswire